|
市場調査レポート
商品コード
1425894
尿検査の世界市場レポート 2024Urinalysis Global Market Report 2024 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。 |
尿検査の世界市場レポート 2024 |
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2~10営業日
|
尿検査の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には8.5%の年間複合成長率(CAGR)で49億1,000万米ドルに成長すると予想されます。 尿検査および診断実践内の予測期間で予想される成長は、いくつかの重要な要因に関連付けられている可能性があります。これらには、迅速かつ即時の診断結果を得るためにポイントオブケア検査(POCT)の導入が増加していること、尿検査がモニタリングと評価において重要な役割を果たしている慢性疾患管理への焦点が当てられていること、高齢化が高齢化につながる影響が含まれます。診断手順を含むヘルスケアサービスの需要、尿分析による早期発見につながる予防ヘルスケアの重視、診断目的で尿検査を利用する遠隔監視や遠隔医療の増加などです。予測期間中に予想される主な動向には、高度な診断検査を必要とする可能性のある革新的な医薬品の承認、尿検査手順の精度と効率を高める技術革新、個別化医療の原則の診断アプローチへの統合、尿検査と関連診断ツールを利用した慢性疾患モニタリングの進化が含まれます。
尿検査市場は、高齢者人口の増加により成長が見込まれています。 65歳以上の高齢者は、免疫力の低下や加齢の影響により、さまざまな病気にかかることがよくあります。この人口統計における健康上の懸念の中で、尿路感染症(UTI)のリスクの増加は注目に値します。 尿検査は、尿の視覚的、化学的、顕微鏡的な成分を検査するもので、糖尿病、腎臓病、泌尿生殖器感染症など、高齢者に蔓延するさまざまな病気を特定し、管理する上で重要な役割を果たします。世界保健機関によると、2030年までに世界で6人が60歳以上となり、その数は14億人に達します。世界の60歳以上の人口は、2050年までに2倍の21億人に増加すると予想されています。特に80歳以上の高齢者の数が増加していることから、高齢者の医療ニーズに対応する尿検査の重要性が強調され、結果として尿検査市場を牽引しています。
尿検査市場の成長は、慢性腎臓病(CKD)の有病率の増加によってさらに加速されています。 CKDは腎臓の機能が徐々に損傷して失われることを特徴とし、血液を効果的に濾過する臓器の能力に影響を与えます。 尿検査は、CKDの特定、監視、管理のための重要な診断ツールとして機能し、腎臓の健康と全体的な身体機能についての貴重な洞察を提供します。米国疾病管理予防センターの報告によると、米国では慢性腎臓病患者が推定3,530万人おり、2020年には約130,522人が末期腎臓病の治療を開始しています。さらに、米国では約786,800人が末期腎臓病を抱えて暮らしています。慢性腎臓病の有病率の増加により、尿検査の需要が増幅され、市場の拡大に貢献しています。
Urinalysis Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on urinalysis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for urinalysis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urinalysis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
A urinalysis, commonly known as a urine test, is a diagnostic examination that assesses the visual, chemical, and microscopic elements present in urine. It evaluates the appearance, concentration, and content of urine, encompassing various tests to detect and measure compounds that are excreted in urine through a single sample. This diagnostic tool is employed to identify and manage a range of health conditions, including diabetes, kidney disease, and urogenital infections.
The primary test types within urinalysis include pregnancy and fertility tests, biochemical urinalysis, and sediment urinalysis. Pregnancy and fertility tests specifically focus on detecting a hormone, human chorionic gonadotropin (HCG), in blood or urine to confirm pregnancy or aid couples in family planning decisions. Regardless of pregnancy intentions, these tests assist in determining pregnancy status. Products used in urinalysis procedures consist of consumables and instruments, applied in diagnosing conditions such as urinary tract infections (UTIs), kidney disease, liver disease, diabetes, hypertension, among others. Urinalysis is utilized across various settings including diagnostic laboratories, hospitals, clinics, home care settings, as well as research laboratories and institutes.
The urinalysis market research report is one of a series of new reports from The Business Research Company that provides urinalysis market statistics, including urinalysis industry global market size, regional shares, competitors with a urinalysis market share, detailed urinalysis market segments, market trends and opportunities, and any further data you may need to thrive in the urinalysis industry. This urinalysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The urinalysis market size has grown strongly in recent years. It will grow from $3.30 billion in 2023 to $3.55 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth observed in the historical period within the field of urinalysis can be attributed to several key factors. These include the increasing healthcare expenditure worldwide, advancements and expansion in healthcare infrastructure, regulatory changes and standardization affecting diagnostic practices, the growing need for drug screening and forensic applications involving urine tests, as well as the development and enhancement of clinical laboratory practices pertaining to urinalysis procedures.
The urinalysis market size is expected to see strong growth in the next few years. It will grow to $4.91 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The anticipated growth in the forecast period within urinalysis and diagnostic practices can be linked to several key factors. These include the increasing adoption of point-of-care testing (POCT) for swift and immediate diagnostic results, the focus on chronic disease management where urine tests play a significant role in monitoring and assessment, the impact of an aging population leading to a higher demand for healthcare services including diagnostic procedures, the emphasis on preventive healthcare leading to early detection through urine analysis, and the rise of remote monitoring and telemedicine practices that utilize urinalysis for diagnostic purposes. Major trends expected in the forecast period encompass innovative drug approvals that may necessitate advanced diagnostic testing, technological innovations enhancing the accuracy and efficiency of urinalysis procedures, the integration of personalized medicine principles into diagnostic approaches, and the evolution of chronic disease monitoring utilizing urine tests and related diagnostic tools.
The urinalysis market is anticipated to witness growth due to the rising geriatric population. The geriatric population, comprising individuals aged 65 and beyond, often experiences various diseases due to lower immunity and the effects of aging. Among the health concerns in this demographic, the increased risk of urinary tract infections (UTI) is notable. Urinalysis, which examines the visual, chemical, and microscopic components of urine, plays a crucial role in identifying and managing various illnesses prevalent in the geriatric population, including diabetes, kidney disease, and urogenital infections. According to the World Health Organization, by 2030, six people in the world will be aged 60 or older, reaching 1.4 billion individuals. The global population aged 60 and older is expected to double to 2.1 billion by 2050. The escalating number of elderly individuals, particularly those aged 80 and older, underscores the significance of urinalysis in addressing the healthcare needs of the geriatric population and, consequently, driving the urinalysis market.
The growth of the urinalysis market is further fueled by the increasing prevalence of chronic kidney disease (CKD). CKD is characterized by the gradual damage and loss of kidney function, impacting the organ's ability to filter blood effectively. Urinalysis serves as a crucial diagnostic tool for the identification, monitoring, and management of CKD, providing valuable insights into kidney health and overall bodily function. The Centers for Disease Control and Prevention reports an estimated 35.3 million people in the U.S. with chronic kidney disease, with about 130,522 initiating treatment for end-stage kidney disease in 2020. Additionally, around 786,800 people in the U.S. are living with end-stage renal disease (ESRD), with 71% expected to undergo dialysis treatment in 2021. The growing prevalence of chronic kidney disease amplifies the demand for urinalysis and contributes to the market's expansion.
Technologically advanced instruments, incorporating artificial intelligence (AI) technology in urine analysis devices, represent a key trend gaining popularity in the urinalysis market. Notably, Olive Diagnostics, an Israel-based health tech company, launched Olive KG in February 2022. This urinalysis sensor device, powered by AI, provides real-time health alerts and early detection of disease progression. Olive KG measures various parameters, including red blood cells, proteins, ketones, nitrites, pH, volume, pressure, color, and urine frequency. Designed as a toilet-mountable Internet of Medical Things (IoMT) device, Olive KG delivers real-time personal data while adhering to GDPR and HIPPA act criteria. The integration of AI technology in urinalysis instruments exemplifies a technological advancement that enhances the efficiency and capabilities of urine analysis, contributing to the market's growth.
Major players in the urinalysis market are actively engaged in developing innovative products, such as urine particle analyzers, to secure a competitive advantage. Urine analyzers are clinical devices designed for automated urine testing, offering capabilities for the detection and quantification of multiple analytes. Urine particle analyzers, in particular, provide enhanced accuracy and precision compared to manual microscopy, contributing to the standardization of urine particle analysis and reducing inter-observer variability. A notable example of this trend is Sysmex Europe SE, a Germany-based automated in vitro diagnostics provider, which introduced the UF-1500 Fully Automated Urine Particle Analyzer in April 2023. This innovative device is engineered to achieve a significant reduction in footprint (approximately 30%) while maintaining high levels of performance and usability. Leveraging cutting-edge fluorescence flow cytometry technology, similar to Sysmex's flagship UF-5000, the UF-1500 caters to diverse customer needs. It serves as a fully automated urinalysis workstation for both developed and emerging markets, as well as backup and satellite systems for extensive facilities that have previously installed the UN-Series. Additionally, the UF-1500 supports connectivity to Sysmex's UC-3500 urine chemistry analyzers.
In a strategic move, Healthy.io Ltd., a U.S.-based healthcare company specializing in remote clinical testing and services, acquired Inui Health for $9 million in June 2022. This acquisition positioned Healthy.io Ltd. to expand its presence in the smartphone diagnostic market by integrating Inui Health's smartphone diagnostics platforms and other at-home testing services. Inui Health, a U.S.-based medical diagnostics company, provides consumers with the convenience of conducting urinalysis at home using a smartphone.
Major companies operating in the urinalysis market report are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Cardinal Health Inc., Abbott Laboratories, Danaher Corporation, Beckman Coulter Inc., Sysmex Corporation, ARKRAY Inc., ACON Laboratories Inc., Bio-Rad Laboratories Inc., URIT Medical Electronic Group Co Ltd., 77 Elektronika Kft, Thermo Fisher Scientific Inc., Teco Diagnostics, Mindray Medical International Limited, Quidel Corporation, Becton Dickinson and Company, EKF Diagnostics, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Guangzhou Wondfo Biotech Co. Ltd., Chembio Diagnostic Systems Inc, Immunostics Inc., Inova Diagnostics Inc., Meridian Bioscience Inc., Fapon Biotech Inc., Nanjing Norman Biological Technology Co. Ltd., OraSure Technologies Inc., Hologic Inc., Randox Laboratories Ltd., Qiagen N.V
North America was the largest region in the urinalysis market in 2023. The regions covered in the urinalysis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the urinalysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The urinalysis market consists of revenues earned by entities by providing urinalysis services by providing visual exam of urine, dipstick test, screening tests, reagents test, culture test and microscopic exam of urine. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinalysis market also includes sales of automated urine analyzers, point of care analyzers, integrated urine analyzers, strip reader connect system equipment which are used in providing urinalysis services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.